Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI310
- Development stage
- Phase 3
- Lead developer
- Innovent Biologics Technology Limited (Shanghai R&D Center)
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
IBI310 is a recombinant, fully human IgG1 monoclonal antibody that targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). It has the same amino acid sequence as ipilimumab and functions as an immune checkpoint inhibitor by blocking CTLA-4, thereby promoting T cell activation and enhancing antitumor immune responses. Developed by Innovent Biologics, often in combination with sintilimab (an anti-PD-1 antibody), IBI310 is being investigated for multiple cancer indications including advanced melanoma, urothelial carcinoma, colorectal cancer (especially MSI-H/dMMR subtypes), cervical cancer, gastric cancer, neuroendocrine tumors, biliary cancer, nasopharyngeal cancer, liver cancer and acral lentiginous melanoma. Clinical studies have shown that IBI310 monotherapy or in combination with sintilimab demonstrates favorable safety profiles and promising antitumor activity[1][3][5][6].
- Brand names
- Tabosun
- Other names
- ipilimumab biosimilar (Innovent Biologics)anti-CTLA-4 antibody (Innovent Biologics)
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on IBI310.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI310.